Programmed death of chemotherapy in non-small-cell lung cancer?
Mené dans 31 pays sur 1 225 patients atteints d'un cancer du poumon non à petites cellules, cet essai multicentrique de phase III, compare l'efficacité, du point de vue de la survie globale, et la toxicité de l'atézolizumab et du docétaxel, après l'échec d'un premier ou d'un second protocole de chimiothérapie
Since the 1980s, platinum-doublet chemotherapy has been the standard of care for first-line therapy in advanced non-small-cell lung cancer without oncogenic drivers, which means in about 85% of white patients.1 However, the benefit of such treatment is limited, with a median overall survival between 8 months and 12 months depending on the patient's Eastern Cooperative Oncology Group (ECOG) performance status and the possibility of adjunctive treatment with bevacizumab and of maintenance therapy.
The Lancet 2016